Compare Royal Caribbean Cruises Ltd (RCL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs BIO-TECHNE Corp — how do they compare? Royal Caribbean Cruises Ltd trades at $283.29 (market cap $75.51B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 6.6× BIO-TECHNE Corp's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (2.13%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and BIO-TECHNE Corp for 63 Days on average.
| RCL | TECH | |
|---|---|---|
Market Cap | $75.51B | $11.37B |
Volume | 2,408,997 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $72.61 |
52-Week Low | $230.30 | $43.31 |
Typical Hold Time | 85 Days | 63 Days |
Enterprise Value | $98.15B | $11.40B |
Dividend Yield | 2.13% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, down 2.58% on the day, amid mixed technical signals with bullish moving averages but overbought RSI levels. Fundamentally, the company shows strong recovery with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income reaching $4.3B. Recent developments include a $3 billion investment in Sandals Resorts and positive analyst sentiment with 51% buy ratings.
The outlook remains positive with analyst consensus target of $346.67 suggesting 23% upside potential. Key opportunities include expanding resort operations and strong booking trends, while risks involve high debt levels, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock presents a growth opportunity with manageable risks for long-term investors.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
